Brief: Eliem Therapeutics Provides Program Updates And An Overview Of Expected Near-Term Milestones

Climb Bio

18/01/2022 13:58

Jan 18 (Reuters) - Eliem Therapeutics Inc  ELYM.O :
    * ELIEM THERAPEUTICS PROVIDES PROGRAM UPDATES AND AN
OVERVIEW OF
EXPECTED NEAR-TERM MILESTONES
    * ELIEM THERAPEUTICS INC - PATIENT DOSING UNDERWAY FOR
ETX-155
PHASE 1B PROOF-OF-CONCEPT STUDY IN EPILEPSY
    * ELIEM THERAPEUTICS - CONTINUES TO EXPECT ITS CURRENT CASH,
CASH
EQUIVALENTS AND MARKETABLE SECURITIES SUFFICIENT TO FUND
OPERATIONS THROUGH LATE 2023
    * ELIEM THERAPEUTICS INC - IND APPLICATION PLANNED IN Q1
2022 FOR
ETX-155 PHASE 2 TRIALS IN MDD AND PMD
    * ELIEM THERAPEUTICS INC - ETX-810 PHASE 2A TRIAL IN
DIABETIC
PERIPHERAL NEUROPATHIC PAIN (DPNP) IS FULLY ENROLLED

Source text for Eikon:  ID:nGNXbMs0jD 
Further company coverage:  ELYM.O